Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Zhang P, Shi S, Xu J, Chen Z, Song L, Zhang X, Cheng Y, Zhang Y, Ye F, Li Z, Yin F, Ji D, Gao H, Li Y, Chen W, Yang M, Weng D, Wu C, Ma Y, Sheng W, Zhao Y, Yin X, Shen W, Su W, Shi M, Fan S, Tan P, Xu Q, Lu M, Shen L.
Zhang P, et al. Among authors: chen z, chen w.
Eur J Cancer. 2024 Mar;199:113539. doi: 10.1016/j.ejca.2024.113539. Epub 2024 Jan 15.
Eur J Cancer. 2024.
PMID: 38237373
Free article.
Clinical Trial.